Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

It's been a long wait since the fourth season of Stranger Things was released, and there's still a while to wait until season 5 finally hits Netflix. However, fans are finally starting to get some ...

After hours: 7:59:01 p.m. EST ...

How much is Novo Nordisk A/S ADR stock worth? Invest with precise valuations. Get Report.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

After hours: February 13 at 6:38:08 PM EST Loading Chart for PRPL ...